These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38480051)

  • 1. Prognostic factors in clinicopathology of oesophagogastric adenocarcinoma: a single-centre longitudinal study of 347 cases over a 20-year period.
    Huang Q; Lew E; Cheng Y; Huang K; Deshpande V; Shinagare S; Yuan X; Gold JS; Wiener D; Weber HC
    Pathology; 2024 Jun; 56(4):484-492. PubMed ID: 38480051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphangiogenesis and prognostic significance of vascular endothelial growth factor C in gastro-oesophageal junction adenocarcinoma.
    Xie LX; Zhai TT; Yang LP; Yang E; Zhang XH; Chen JY; Zhang H
    Int J Exp Pathol; 2013 Feb; 94(1):39-46. PubMed ID: 23317352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histopathologic Features are more Important Prognostic Factors than Primary Tumour Location in Gastro-oesophageal Adenocarcinoma Treated with Preoperative Chemoradiation and Surgery.
    Vošmik M; Laco J; Sirák I; Dvořák J; Lochman P; Hodek M; Malá P; Rejchrt S; Repák R; Leško M; Ferko A; Ryška A; Melichar B; Petera J
    Pathol Oncol Res; 2018 Apr; 24(2):373-383. PubMed ID: 28550507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry.
    Alvarez-Manceñido F; Jimenez-Fonseca P; Carmona-Bayonas A; Arrazubi V; Hernandez R; Cano JM; Custodio A; Pericay Pijaume C; Aguado G; Martínez Lago N; Sánchez Cánovas M; Cacho Lavin D; Visa L; Martinez-Torron A; Arias-Martinez A; López F; Limón ML; Vidal Tocino R; Fernández Montes A; Alsina M; Pimentel P; Reguera P; Martín Carnicero A; Ramchandani A; Granja M; Azkarate A; Martín Richard M; Serra O; Hernández Pérez C; Hurtado A; Gil-Negrete A; Sauri T; Morales Del Burgo P; Gallego J
    Gastric Cancer; 2021 Jul; 24(4):926-936. PubMed ID: 33651195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial.
    Rivera F; Izquierdo-Manuel M; García-Alfonso P; Martínez de Castro E; Gallego J; Limón ML; Alsina M; López L; Galán M; Falcó E; Manzano JL; González E; Muñoz-Unceta N; López C; Aranda E; Fernández E; Jorge M; Jiménez-Fonseca P
    Eur J Cancer; 2021 Mar; 145():158-167. PubMed ID: 33485079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison of clinicopathological features and prognosis between adenocarcinoma of esophagogastric junction and adenocarcinoma of gastric antrum].
    Zhu Z; Wang Y; Li F; Gao J; Han B; Wang R; Xue Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):149-155. PubMed ID: 30799537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of gastro-oesophageal junction carcinomas in Chinese versus American patients.
    Huang Q; Fan X; Agoston AT; Feng A; Yu H; Lauwers G; Zhang L; Odze RD
    Histopathology; 2011 Aug; 59(2):188-97. PubMed ID: 21884197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relevance of the Siewert classification in the era of multimodal therapy for adenocarcinoma of the gastro-oesophageal junction.
    Curtis NJ; Noble F; Bailey IS; Kelly JJ; Byrne JP; Underwood TJ
    J Surg Oncol; 2014 Mar; 109(3):202-7. PubMed ID: 24243140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma.
    Propper D; Jones K; Anthoney DA; Mansoor W; Ford D; Eatock M; Agarwal R; Inatani M; Saito T; Abe M; Evans TR
    BMC Cancer; 2016 Oct; 16(1):779. PubMed ID: 27724887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours.
    Thomaschewski M; Hummel R; Petrova E; Knief J; Wellner UF; Keck T; Bausch D
    World J Gastroenterol; 2018 Apr; 24(13):1429-1439. PubMed ID: 29632424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Esophageal adenocarcinoma heterogeneity in clinicopathology and prognosis: A single center longitudinal study of 146 cases over a 20-year period.
    Huang Q; Lew E; Cheng Y; Shinagare S; Deshpande V; Gold JS; Wiener D; Weber HC
    Ann Diagn Pathol; 2024 Jun; 70():152285. PubMed ID: 38518703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to classify adenocarcinomas of the esophagogastric junction: as esophageal or gastric cancer?
    Gertler R; Stein HJ; Loos M; Langer R; Friess H; Feith M
    Am J Surg Pathol; 2011 Oct; 35(10):1512-22. PubMed ID: 21934477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telomerase activity and patient survival after surgery for gastric and oesophageal cancer.
    Usselmann B; Newbold M; Morris AG; Nwokolo CU
    Eur J Gastroenterol Hepatol; 2001 Aug; 13(8):903-8. PubMed ID: 11507353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of immune-checkpoint inhibitors in metastatic gastric or gastroesophageal junction adenocarcinoma by patient subgroups: A systematic review and meta-analysis.
    Kundel Y; Sternschuss M; Moore A; Perl G; Brenner B; Goldvaser H
    Cancer Med; 2020 Oct; 9(20):7613-7625. PubMed ID: 32869544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Personalizing risk stratification by addition of PAK1 expression to TNM staging: improving the accuracy of clinical decision for gastroesophageal junction adenocarcinoma.
    Li Z; Zou X; Xie L; Chen H; Chen Y; Yeung SC; Zhang H
    Int J Cancer; 2015 Apr; 136(7):1636-45. PubMed ID: 25159681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved survival in resected oesophageal and gastric adenocarcinomas over a decade: the Royal Marsden experience 2001-2010.
    Fontana E; Smyth EC; Cunningham D; Rao S; Watkins D; Allum WH; Thompson J; Waddell T; Peckitt C; Chau I; Starling N
    Gastric Cancer; 2016 Oct; 19(4):1114-1124. PubMed ID: 26541768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of the distinct genomic features in gastroesophageal junction adenocarcinoma and its Siewert subtypes.
    Geng Q; Lao J; Zuo X; Chen S; Bei JX; Xu D
    J Pathol; 2020 Nov; 252(3):263-273. PubMed ID: 32715475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials.
    Chau I; Norman AR; Cunningham D; Oates J; Hawkins R; Iveson T; Nicolson M; Harper P; Seymour M; Hickish T
    Ann Oncol; 2009 May; 20(5):885-91. PubMed ID: 19164454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histopathological regression predicts treatment outcome in locally advanced esophagogastric adenocarcinoma.
    Spoerl S; Novotny A; Al-Batran SE; Lordick F; Thuss-Patience P; Pauligk C; Haller B; Feith M; Lorenzen S
    Eur J Cancer; 2018 Feb; 90():26-33. PubMed ID: 29272782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic implications of
    Knief J; Reddemann K; Lazar-Karsten P; Herhahn T; Petrova E; Wellner U; Thorns C
    J Clin Pathol; 2017 Mar; 70(3):274-276. PubMed ID: 28011578
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.